Advertisement

Obesity Surgery

, Volume 19, Issue 4, pp 534–536 | Cite as

Succinylcholine: A Drug to Avoid in Bariatric Surgery

  • Talar Tejirian
  • Catherine E. Lewis
  • James Conner
  • Candice Jensen
  • Erik Dutson
  • Amir MehranEmail author
Case Report

Abstract

Succinylcholine is a paralytic agent regularly utilized in anesthesia. There are numerous adverse effects of succinylcholine ranging from mild to fatal; one such effect is succinylcholine myalgia. We report the case of a 34-year-old woman who received succinylcholine while undergoing laparoscopic Roux-en-Y gastric bypass and later developed succinylcholine myalgia leading to a prolonged hospital stay and subsequent pneumonia. In the presence of suitable alternative paralytic agents, succinylcholine should be avoided in patients undergoing bariatric surgery. The use of a designated anesthesia team familiar with bariatric operations can help maximize peri-operative management and minimize complications.

Keywords

Obstructive Sleep Apnea Gastric Bypass Succinylcholine Rocuronium Motor Neuron Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bettelli G. Which muscle relaxants should be used in day surgery and when. Curr Opin Anaesthesiol 2006;19:600–5.CrossRefGoogle Scholar
  2. 2.
    Schreiber JU, Lysakowski C, Fuchs-Buder T, et al. Prevention of succinylcholine-induced fasciculation and myalgia. Anesthesiology 2005;103:877–84.CrossRefGoogle Scholar
  3. 3.
    Katre AM, Parab SG. Post-operative muscle pain and serum potassium changes following self-taming of succinylcholine-induced fasciculations. J Postgrad Med 1982;28:18–23.PubMedGoogle Scholar
  4. 4.
    Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232:515–29.CrossRefGoogle Scholar
  5. 5.
    Collier B, Goreja MA, Duke BE. Postoperative rhabdomyolysis with bariatric surgery. Obesity Surgery 2003;13:941–3.CrossRefGoogle Scholar
  6. 6.
    Mognol P, Vignes S, Chosidow D, et al. Rhabdomyolysis after laparoscopic bariatric surgery. Obesity Surgery 2004;14:91–4.CrossRefGoogle Scholar
  7. 7.
    Wong SF, Chung F. Succinylcholine-associated postoperative myalgia. Anaesthesia 2000;55:144–52.CrossRefGoogle Scholar
  8. 8.
    Brodsky JB, Foster PE. Correspondence: succinylcholine and morbid obesity. Obesity Surgery 2003;13:138–9.CrossRefGoogle Scholar
  9. 9.
    Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 20006;102:438–42.CrossRefGoogle Scholar
  10. 10.
    McNatt SS, Longhi JJ, Goldman CD, et al. Surgery for obesity: a review of the current state of the art and future directions. J of Gastrointestinal Surgery 2007;11:377–97.CrossRefGoogle Scholar
  11. 11.
    Flier S, Knape TA. How to inform a morbidly obese patient on the specific risk to develop postoperative pulmonary complications using evidence-based methodology. European Journal of Anaesthesiology 2006;23:154–9.CrossRefGoogle Scholar
  12. 12.
    Kazanjian PE. Anesthesia complications. In: Mulholland MW, Doherty GA, editors. Complications in surgery. Baltimore: Lippincott Williams & Wilkins; 2005. p. 78–80.Google Scholar
  13. 13.
    Lindgren L, Saarnivaara L. Increase in intragastric pressure during suxamethonium-induced muscle fasciculations in children: inhibition by alfentanil. Br J Anaesthesiology 1988;60:176–9.CrossRefGoogle Scholar
  14. 14.
    Mejía-Rivas MA, Herrera-López A, Hernández-Calleros J, et al. Gastroesophageal reflux disease in morbid obesity: the effect of roux-en-y gastric bypass. Obes Surg. 2008;18:Oct (in press).CrossRefGoogle Scholar
  15. 15.
    El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci 2008;53:2307–12.CrossRefGoogle Scholar
  16. 16.
    Morgan GE, Mikhail MS, Murray MJ. Clinical Anesthesiology. Fourth Edition. McGraw Hill. 2005:213–215.Google Scholar
  17. 17.
    Collins CP, Beirne OR. Concepts in the prevention and management of malignant hyperthermia. J of Oral and Maxillofacial Surgery 2003;61:1340–5.CrossRefGoogle Scholar
  18. 18.
    Lysakowski C, Suppan L, Czarnetzki C, et al. Impact of the intubation model on the efficacy of rocuronium during rapid sequence intubation: systematic review of randomized trials. Acta Anaesthesiol Scand 2007;51:848–57.CrossRefGoogle Scholar
  19. 19.
    Schering-Plough, Schering-Plough News Release. U.S. FDA Issues Action Letter for Sugammadex. http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=1182475. Accessed August 26, 2008.
  20. 20.
    Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008;109:188–97.CrossRefGoogle Scholar
  21. 21.
    Chand B, Gugliotti D, Schauer P, et al. Perioperative management of the bariatric surgery patient: Focus on cardiac and anesthesia considerations. Clevland Clinic J of Med 2006;73(Supplement 1):S51–6.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Talar Tejirian
    • 1
  • Catherine E. Lewis
    • 1
  • James Conner
    • 1
  • Candice Jensen
    • 1
  • Erik Dutson
    • 1
  • Amir Mehran
    • 1
    • 2
    Email author
  1. 1.Department of SurgeryDavid Geffen School of Medicine, University of CaliforniaLos AngelesUSA
  2. 2.Department of SurgeryUniversity of CaliforniaLos AngelesUSA

Personalised recommendations